Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medexus Pharmaceuticals Inc. T.MDP

Alternate Symbol(s):  T.MDP.DB | T.MDP.W | MEDXF

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 


Q4 is out. Financial Highlights Delivered total revenue of $20.3 million in fiscal Q4 2022, an increase of 15% compared to fiscal Q4 2021 and, as expected, a decrease of 5% compared to more

When ... ?

Next fins ...?  rate and reply

RE:Deal for Gleolan in the United States

When ???????  rate and reply

Deal for Gleolan in the United States

Medexus has acquired exclusive rights to commercialize Gleolan in the United States, complementing Medexus’s existing rights to Gleolan in Canada Gleolan is an optical imaging agent more

EyePoint: Appoints Michael C. Pine as Chief of Dev+Strategy

Not sure how this will effect MDP but it is definitely is a good move for Pine. "Most recently, Mr. Pine was a Senior Vice President of Business Development and Strategy at more

RE:RE:Type A Meeting with FDA Granted for Treosulfan

Excellent news on the Type A meeting but we are still 2 to 6 months out. Hoping to hear excellent numbers in the next financials. I've moved my buy in up by 4 months. I'll be looking to more

RE:Type A Meeting with FDA Granted for Treosulfan

Lets hope the type A's have a productive meeting and clear way forward. So we can get back to where it should be trading. I was grateful for the dip so I could av dn. Thanks all! Russ  rate and reply

I bailed last week

I maybe back in 6 months or so.  rate and reply

Good price action on low volume

up 6.3%. I'm wondering about the Type A meeting. If it is just about the numbers then approval could be 60 to 90+ away, depending on how fast they can present the data. I'm not sure about more

What is Type A meeting

I got this from a Yahoo Finance. Basically good new but it takes time. Type A Meetings The FDA and the applicants of regulatory filings interact with each other during the review period more

RE:Type A Meeting with FDA Granted for Treosulfan

Good news. If all goes well this will be an easy double in my opinion.  rate and reply

Type A Meeting with FDA Granted for Treosulfan

TORONTO and CHICAGO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) today announced that the U.S. more

to Present at the Benzinga Global Small Cap Conference

TORONTO and CHICAGO and MONTREAL, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, more

RE:Pricking thumb senses something is up

This seems to be the season for large increases without news. Compression triangles are being tripped for large increases. Pricking thumb? Pricking balloon? cleareye.  rate and reply

Pricking thumb senses something is up

Good move to the upside however volume, better, is still small so maybe there is news. If this stays on an upward trend then yes something good is coming, in my opion which is not expert opinion.  rate and reply

Smallcap Discoveries interview with CEO  rate and reply

Good news out the other day

Medexus Announces Expanded Availability of Trecondyv® (treosulfan) in Canada If you read the article you get the gist that Doctors are very happy with the results they get from the drug. FDA more

Good move to the upside today up 6.6%

Event hough I'm down on this stock, buying on the dips has made me money. I'm trading this right now trying to reduce the pain as much as I can.  rate and reply

MDP is a wait and see stock

The FDA wanted the numbers on Treos crunched to their standards and that is a medac problem not MDP. However it is a waiting game for those numbers to come in and this stock to go beyond $8 to $ more

RE:RNG is hot!

I apologize to the board this was meant for GRN not MDP  rate and reply